According to a Celltrion press release, this week investigators presented twelve-month data from a UK-wide, three-year prospective observational study showing comparable efficacy between CT-P13 (Celltrion’s biosimilar infliximab), reference infliximab (Johnson and Johnson’s Remicade), and adalimumab (AbbVie’s Humira). The press release reports that the Personalised Anti-TNF therapy in Crohn’s disease Study (PANTS) also showed remission rates of 39.0% for CT-P13 at week 54, as compared to 39.7% and 32.7% for reference infliximab and adalimumab, respectively.

The press release states that the data presented at the 13th Congress of the European Crohn’s and Colitis Organisation (ECCO) indicated clinical effectiveness, safety and immunogenicity of Celltrion’s infliximab in patients with Crohn’s disease.